H.C. Wainwright analyst Ed Arce raised the firm’s price target on Akero Therapeutics (AKRO) to $75 from $72 and keeps a Buy rating on the shares following the Q4 report. The firm expects EFX’s F2-F3 metabolic dysfunction-associated steatohepatitis accelerated approval in the first half of 2028.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Akero Therapeutics price target lowered to $90 from $96 at Morgan Stanley
- Akero Therapeutics: Buy Rating Backed by Groundbreaking Clinical Results and Strong Financial Position
- Akero Therapeutics Reports Promising Clinical Trial Results
- Akero Therapeutics: Strong Financial Health and Promising Clinical Trial Results Drive Buy Rating
- Biotech Alert: Searches spiking for these stocks today
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue